InsidersTradesSigma
Follow the Impedimed Limited share price and the full directors' dealings record of the company, a publicly traded company based in Australia. Shares trade on the AU market, under the authority of ASX. Operating in the Health Care sector, Impedimed Limited has recorded 6 insider filings. Market capitalisation: €22m. The latest transaction was filed on 3 June 2026 (Purchase). Among the most active insiders: FORM 603. All data is accessible without an account.
6
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Impedimed Limited Strong Buy (bullish), based on 4 analysts. Average price target: A$0.02.
2Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,999 of 28,803 companies
28.1
score / 100
Value8
Quality48
FCF yld-22%
Earn yld-33%
EV/EBITDA·
ROE-118%
Gross mgn86%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 June 2026
About Impedimed Limited
Impedimed Limited is a medical technology company focused on developing solutions for the diagnosis and management of lymphatic diseases. It is listed on the XASX market.